key: cord-1032723-50rqrd7n authors: Benotmane, I.; Velay, A.; Thaunant, O.; Gautier-Vargas, G.; Olagne, J.; Fafi-Kremer, S.; Caillard, S. title: Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the omicron variant in kidney transplant patients date: 2022-03-23 journal: nan DOI: 10.1101/2022.03.21.22272669 sha: d49cc101fb19824a71616f144d435316d355d6d7 doc_id: 1032723 cord_uid: 50rqrd7n The combination of cilgavimab-tixagevimab (Evusheld, Astra Zeneca) became the mainstay for protecting transplant recipients with poor response to vaccination against the omicron variant. Serum neutralizing capacity against SARS-CoV-2 is positively associated with protection against severe forms of Covid-19. Both anti-RBD IgG titers and neutralizing antibody titers against the omicron BA.1 variant were measured in serum samples collected from 63 adult kidney transplant recipients who received prophylactic injections of Evusheld. Patients who received prophylactic Ronapreve (casirivimab-imdevimab, n = 39) and those who were infected with SARS-CoV-2 during the fifth wave of the pandemic (n = 14) served as negative and positive controls, respectively. After a median interval from injection of 29 days (interquartile range 29-33 days), only 9.5% of patients who received Evusheld were able to neutralize the omicron variant compared to 71% of patients who were infected with SARS-CoV-2 and 2.6% of those who received Ronapreve. Interestingly, convalescent patients displayed higher levels of neutralizing antibodies than those who received Evusheld (median: 2.3 log IC50, IQR: 1.5-2.7 versus 0.00 log IC50, IQR: 0- 0.05; p<0.001). A high interindividual variability in anti-RBD IgG titers was observed after Evusheld (range: 262-7032 BAU/mL). This variability was largely explained by the patients' body mass index, which showed an inverse correlation with anti-RBD IgG titers. These findings suggest that Evusheld given at a dose of 300 mg is not sufficient to elicit an anti-RDB titer that confers in vivo neutralizing activity and support recent FDA recommendations, derived from in vitro models, regarding the need to increase the dose of Evusheld. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.21.22272669 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. The combination of cilgavimab-tixagevimab (Evusheld TM , Astra Zeneca) became the mainstay for protecting transplant recipients with poor response to vaccination against the omicron variant. Serum neutralizing capacity against SARS-CoV-2 is positively associated with protection against severe forms of Covid-19. Both anti-RBD IgG titers and neutralizing antibody titers against the omicron BA.1 variant were measured in serum samples collected from 63 adult kidney transplant recipients who received prophylactic injections of Evusheld TM . Patients who received prophylactic Ronapreve TM (casirivimab-imdevimab, n = 39) and those who were infected with SARS-CoV-2 during the fifth wave of the pandemic (n = 14) served as negative and positive controls, respectively. After a median interval from injection of 29 days (interquartile range 29-33 days), only 9.5% of patients who received Evusheld TM were able to neutralize the omicron variant compared to 71% of patients who were infected with SARS-CoV-2 and 2.6% of those who received Ronapreve TM . Interestingly, convalescent patients displayed higher levels of neutralizing antibodies than those who received EvusheldTM (median: 2.3 log IC50, IQR: 1.5-2.7 versus 0.00 log IC50, IQR: 0&[ndash] 0.05; p<0.001). A high interindividual variability in anti-RBD IgG titers was observed after Evusheld TM (range: 262-7032 BAU/mL). This variability was largely explained by the patients'body mass index, which showed an inverse correlation with anti-RBD IgG titers. These findings suggest that Evusheld TM given at a dose of 300 mg is not sufficient to elicit an anti-RDB titer that confers in vivo neutralizing activity and support recent FDA recommendations, derived from in vitro models, regarding the need to increase the dose of Evusheld TM . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Both anti-RBD IgG titers and neutralizing antibody titers against the omicron BA. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 1B ). This variability was largely explained by the patients' body mass index, which showed an inverse correlation with anti-RBD IgG titers ( Figure 1C ). Further analysis revealed that patients with anti-RBD titers <2500 BAU/mL after Evusheld™ injection had no neutralizing activity (Figure 2) . Furthermore, seven patients in this cohort developed symptomatic Covid-19 including two who required hospitalization. All had negative neutralizing activity at the time of diagnosis. The results of our study indicate that less than 10% of patients who received Evusheld™ were able to neutralize the omicron BA.1 variant at 29 post-injection days. These findings suggest that Evusheld™ given at a dose of 300 mg is not sufficient to elicit an anti-RDB titer that confers in vivo neutralizing activity. This is in line with a recent study showing that anti-RBD levels of approximately 8500 BAU/mL were associated with serum neutralizing activity against omicron in transplant recipients who received three vaccine doses (5) . Our data also support recent FDA recommendations (6), derived from in vitro models, regarding the need to increase the dose of Evusheld TM . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Correlation between body mass index (kg/m 2 ) and anti-RBD IgG titers (BAU/mL, Abbott Architect, Chicago IL, USA) measured at 28 days after Evusheld™ injection (300 mg) in 27 patients who did not receive Ronapreve™ before Evusheld™; r 2 =0.595. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. COVID-19 vaccination in kidney transplant recipients REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme Considerable escape of SARS-CoV-2 Omicron to antibody neutralization Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients Neutralization against Omicron variant in transplant recipients after three-doses of mRNA vaccine Epub ahead of print Sophie Caillard and Olivier Thaunat have received consultancy fees from Astra Zeneca. The other authors have no conflicts of interest to declare.